OpenAI GPT-5 lowers cell-free protein synthesis costs by 40%

AI Impact Summary

OpenAI's GPT-5, integrated with Ginkgo Bioworks' automation, significantly reduces the cost of cell-free protein synthesis by 40%. This represents a major advancement for researchers and developers in areas like drug discovery and synthetic biology, potentially accelerating innovation and reducing R&D expenses. The new pricing model will likely attract more users to this combined platform.